编号：2021-004 1 证券代码：300529 证券简称：健帆生物 债券代码：123117 债券简称：健帆转债 健帆生物科技集团股份有限公司 投资者关系活动记录表 | --- | --- | --- | |-------------------|---------------------------------|---------------------------------------------------------------------------------------------------------------------------| | | □ 特定对象调研 | □ 分析师会议 | | 投资者关 | □ 媒体采访 □ | 业绩说明会 | | 系活动类 | □ 新闻发布会 | □ 路演活动 | | 别 | □ 现场参观 √ | 其他（电话会议） | | | 安信证券：马帅、李奔 | | | 参与单位 名称及人 | | 高瓴资本、广发证券、大成基金、富国基金、招商基金、金信基金、 融通基金、华安财保资管、申万菱信基金、中欧基金、南方基金、汇 | | 员姓名 | 际金融、东吴基金等 | ...

编号：2022-001 证券代码：300529 证券简称：健帆生物 债券代码：123117 债券简称：健帆转债 健帆生物科技集团股份有限公司 投资者关系活动记录表 | --- | --- | --- | |-------------------|-------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------| | | | | | | □ 特定对象调研 | □ 分析师会议 | | 投资者关 | □ 媒体采访 □ | ...

证券代码：300529 证券简称：健帆生物 债券代码：123117 债券简称：健帆转债 编号：2022-005 健帆生物科技集团股份有限公司 投资者关系活动记录表 | --- | --- | --- | |------------------------|---------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------| | | | | | | □ 特定对象调研 | □ 分析师会议 | | 投资者关 | □ 媒体采访 | □ 业绩说明会 | | 系活动类 | □ 新闻发布会 | □ 路演活动 | | 别 | □ 现场参观 | √ 其他（投资者说明会） | | 参与人员 | 通过 "2022 的投资者 | 年广东上市公司投资者网上集体接待日 " 线上参与公司投资者说明会 | | 时间 | 202 ...

编号：2022-004 1 证券代码：300529 证券简称：健帆生物 债券代码：123117 债券简称：健帆转债 健帆生物科技集团股份有限公司 投资者关系活动记录表 | --- | --- | --- | |------------------------|-----------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------| | | | | | | □ 特定对象调研 | □ 分析师会议 | | 投资者关 | □ 媒体采访 | □ 业绩说明会 | | 系活动类 | □ 新闻发布会 | □ 路演活动 | | 别 | □ 现场参观 | √ 其他（电话会议） | | 参与人员 | | 兴业证券、中信建投、申万宏源、中泰证券、西南证券、国金证券、天风证券、 海通证券、广发证券、安信证券及 ...

编号：2022-006 1 证券代码：300529 证券简称：健帆生物 债券代码：123117 债券简称：健帆转债 健帆生物科技集团股份有限公司 投资者关系活动记录表 | --- | --- | --- | |------------------------|-------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------| | | | | | | □ ...

Revenue and Profit - The company's revenue for Q3 2022 was ¥471,416,012.01, a decrease of 20.58% compared to the same period last year[3] - Net profit attributable to shareholders for Q3 2022 was ¥125,294,456.51, down 48.43% year-on-year[3] - The net profit after deducting non-recurring gains and losses was ¥120,418,512.92, a decrease of 47.86% compared to the previous year[3] - The company's basic earnings per share for Q3 2022 was ¥0.17, down 43.33% year-on-year[3] - Total operating revenue for the current period reached ¥2,025,701,872.97, an increase of 13.7% compared to ¥1,781,805,266.01 in the previous period[18] - Operating profit for the current period was ¥1,021,591,465.64, slightly up from ¥1,013,971,252.26 in the previous period, reflecting a growth of 0.1%[19] - Net profit attributable to shareholders of the parent company was ¥873,450,879.06, compared to ¥863,085,578.68 in the previous period, indicating a growth of 1.4%[19] - Basic earnings per share increased to ¥1.10 from ¥1.08 in the previous period, while diluted earnings per share rose to ¥1.08 from ¥1.07[20] Assets and Liabilities - The total assets at the end of Q3 2022 reached ¥5,144,905,239.58, an increase of 6.96% from the end of the previous year[3] - As of September 30, 2022, the total assets amounted to approximately CNY 5.14 billion, an increase from CNY 4.81 billion at the beginning of the year[15] - The total liabilities as of September 30, 2022, were approximately CNY 1.53 billion, compared to CNY 1.43 billion at the beginning of the year, indicating an increase of about 7.7%[16] - The company's equity attributable to shareholders rose to approximately CNY 3.59 billion from CNY 3.36 billion, marking an increase of about 6.9%[17] Cash Flow - The cash flow from operating activities for the year-to-date was ¥525,086,171.92, a decrease of 21.17% compared to the previous year[3] - Cash flow from operating activities generated a net amount of ¥525,086,171.92, down from ¥666,139,337.01 in the previous period, a decrease of 21.2%[21] - Cash inflow from investment activities totaled ¥2,113,400,711.80, compared to ¥2,330,043,064.21 in the previous period, reflecting a decrease of 9.3%[21] - The net cash flow from investing activities was -254,490,340.21 CNY, an improvement from -1,329,117,858.58 CNY in the previous year[22] - Total cash inflow from financing activities was 179,546,337.73 CNY, down from 1,192,629,344.86 CNY year-over-year[22] - The net cash flow from financing activities was -545,642,142.51 CNY, contrasting with a positive flow of 371,088,002.33 CNY in the previous year[22] - The cash and cash equivalents at the end of the period totaled 2,040,617,963.33 CNY, an increase from 1,278,225,616.54 CNY year-over-year[22] - The net decrease in cash and cash equivalents was -273,801,552.29 CNY, slightly better than -291,823,998.55 CNY in the previous year[22] Expenses and Costs - Research and development expenses increased by 68.86% year-on-year, totaling ¥162,284,135.93[8] - Total operating costs for the current period were ¥1,065,873,628.42, up from ¥821,488,233.10, representing a growth of 29.8%[18] - The company reported a tax expense of ¥146,865,226.90, slightly up from ¥146,513,524.66 in the previous period[19] Shareholder Information - The total number of ordinary shareholders reached 49,514, with the largest shareholder holding 43.97% of the shares[11] - The company’s largest shareholder, Dong Fan, holds 355,131,867 shares, representing a significant portion of the total equity[11] Inventory and Prepayments - The company reported a significant increase in inventory, which rose by 59.55% due to preparations for annual sales growth[6] - The inventory increased to approximately CNY 313.59 million from CNY 196.55 million, reflecting a growth of about 59.6%[15] - The company has seen a 101.71% increase in prepayments, primarily due to increased procurement prepayments[6] Other Financial Metrics - The weighted average return on equity was 3.62%, down 3.68% from the previous year[3] - The company received a VAT refund of approximately CNY 10.84 million, a significant increase of 3001.52% compared to the same period last year[9] - Cash paid for purchasing goods and services decreased by 30.76% to CNY 72.69 million, primarily due to a reduction in government subsidies received[9] - Cash paid to employees increased by 60.31% to CNY 478.19 million, attributed to an increase in employee count and average salary[9] - Total cash outflow from operating activities rose by 34.10% to CNY 1.72 billion, driven by increased procurement costs and employee compensation[9] - Cash inflow from financing activities decreased by 84.95% to CNY 179.55 million, mainly due to the absence of convertible bond issuance this year[10] - The company paid dividends amounting to CNY 720 million, reflecting a 35.59% increase compared to the previous year[10] Stock Options - The company has 243,016 stock options available for exercise in 2022, with 226,877 options exercised during the reporting period, leaving 16,138 options unexercised[14] Audit Status - The third quarter report was not audited, which may affect the perception of financial reliability[23]

证券代码：300529 证券简称：健帆生物 公告编号：2022-101 债券代码：123117 债券简称：健帆转债 健帆生物科技集团股份有限公司 关于参加 2022 年广东上市公司投资者网上集体接待日活动 的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记 载、误导性陈述或重大遗漏。 为进一步加强与投资者的交流沟通，健帆生物科技集团股份有限公司（以下 简称"公司"）将参加由广东证监局、广东上市公司协会共同举办的"心系投资者， 携手共行动——筑牢资本市场稳健发展基石"——2022年广东上市公司投资者网 上集体接待日活动。现将有关事项公告如下： 本次投资者集体接待日活动将在深圳市全景网络有限公司提供的网上平台、 采取网络远程的方式举行 ， 投资者可以登录 " 全 景 • 路演天下 " 网 站 （http://rs.p5w.net）参与公司本次投资者集体接待日活动，活动时间为 2022 年 9 月 22 日（星期四）15:50-16:50。 届时公司董事长、总经理、董事会秘书董凡先生，财务中心副总监廖雪云女 士及证券事务代表黄聪女士将通过网络在线方式，与投资者就公司治理、经营情 况及发展战 ...

Financial Performance - The company reported a revenue of RMB 500 million for the first half of 2022, representing a year-on-year increase of 20%[23] - The net profit attributable to shareholders was RMB 100 million, up 15% compared to the same period last year[23] - The company's revenue for the reporting period reached ¥1,554,285,860.96, representing a 30.80% increase compared to ¥1,188,254,809.14 in the same period last year[33] - Net profit attributable to shareholders was ¥748,156,422.55, up 20.64% from ¥620,140,698.34 year-on-year[33] - The net profit after deducting non-recurring gains and losses was ¥698,925,841.27, reflecting a 19.52% increase from ¥584,793,617.60 in the previous year[33] - The company achieved a revenue of 1.554 billion yuan in the first half of 2022, representing a year-on-year growth of 30.80%[76] - The net profit attributable to shareholders reached 748 million yuan, an increase of 20.64% compared to the same period last year[76] Market Expansion and Strategy - The company plans to launch two new products in Q4 2022, focusing on advanced blood purification technologies[23] - Future guidance indicates a projected revenue growth of 25% for the full year 2022[23] - The company is expanding its market presence in Southeast Asia, targeting a 10% market share by the end of 2023[23] - A strategic acquisition of a local competitor is expected to be finalized by Q1 2023, enhancing the company's product portfolio[23] - The company has established partnerships with over 80 large hospitals for clinical research[66] - The company has ongoing major non-equity investments, including a blood dialysis product production base project with an investment of ¥3,890,352.25, which is 98% complete[118] Research and Development - The company has allocated RMB 50 million for R&D in new technologies for blood purification systems[23] - The company invested 99.8231 million yuan in R&D, a 95.09% increase, accounting for 6.42% of total revenue[66] - The company employs a combined research and development model, focusing on independent and collaborative R&D to enhance core technology and efficiency[50] - The company has a total of 288 authorized patents, including 59 invention patents[66] - The company has received 24 authorized patents in 2022, including 6 invention patents, bringing the total to 288 patents[90] Product Development and Innovation - The company has expanded its product offerings to include kidney nutrition products as part of its business development strategy[32] - The company launched a new product, the cytokine adsorption column, specifically designed for sepsis patients, which was officially marketed in December 2021[44] - The Future F20 blood purification device received its Class III medical device registration in 2020 and EU CE certification in January 2021, supporting multiple blood adsorption treatment modes[48] - The HA130 multi-center RCT study published in August 2022 demonstrated that the HP (HA130) + LFHD group had a 63% reduction in itching scores, while the HP (HA130) + HFHD group had a 51% reduction, indicating significant efficacy in treating uremic pruritus[77] - The expert consensus on hemoperfusion in maintenance hemodialysis patients was published, recommending hemoperfusion treatment for patients with severe uremic-related symptoms, providing a standardized clinical application guideline[78] Financial Management and Investments - No cash dividends will be distributed for the current fiscal year, as the company focuses on reinvestment[6] - The total investment during the reporting period was ¥158,782,343.43, a decrease of 32.23% compared to the same period last year[113] - The company has established a special fund for artificial liver treatment, supporting 58 research projects nationwide[86] - The company reported a total of 180 million yuan in entrusted financial management, with actual returns of 1,198.53 million yuan during the reporting period[136] Operational Efficiency and Challenges - The net cash flow from operating activities decreased by 8.87% to ¥448,667,761.61 from ¥492,315,765.05 in the previous year[33] - The company's weighted average return on equity was 20.69%, down from 22.94% in the previous year, indicating a decline in profitability[33] - The company faces risks from increasing competition in the blood perfusion market, which may lead to price reductions and impact future profitability[146] - The company is subject to regulatory risks, as changes in national policies could alter the competitive landscape of the medical device industry[146] Social Responsibility and Community Engagement - The company made charitable donations totaling ¥710,000 in the first half of 2022, contributing to various social responsibility initiatives[96] - The company donated a total of 7.9 million CNY for social welfare, including 3.72 million CNY in medical supplies to Xi'an[164] Corporate Governance and Shareholder Information - The company held its first extraordinary general meeting of 2022 on February 11, with an investor participation rate of 49.76%[151] - The company plans not to distribute cash dividends or issue bonus shares for the semi-annual period[153] - The total number of shares increased from 805,497,338 to 805,497,338, with a net increase of 3,184,940 restricted shares[193] - The chairman and CEO, Dong Fan, increased his shareholding by 4,303,095 shares, amounting to 199,994,176.14 CNY during the reporting period[193]

健帆生物科技集团股份有限公司 2022 年第一季度报告全文 1 证券代码：300529 证券简称：健帆生物 公告编号：2022-044 债券代码：123117 债券简称：健帆转债 健帆生物科技集团股份有限公司 2022 年第一季度报告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导 性陈述或重大遗漏。 重要内容提示: 1.董事会、监事会及董事、监事、高级管理人员保证季度报告的真实、准确、完整，不存在虚假记载、误导性陈述或重大遗 漏，并承担个别和连带的法律责任。 2.公司负责人、主管会计工作负责人及会计机构负责人(会计主管人员)声明：保证季度报告中财务信息的真实、准确、完整。 3.第一季度报告是否经过审计 □ 是 √ 否 一、主要财务数据 (一)主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 | --- | --- | --- | --- | |-----------------------------------------------------|------------------|------------------|------------------- ...

健帆生物科技集团股份有限公司 2021 年年度报告全文 证券代码：300529 证券简称：健帆生物 公告编号：2022-033 债券代码：123117 债券简称：健帆转债 健帆生物科技集团股份有限公司 2021 年年度报告 2022 年 04 月 1 健帆生物科技集团股份有限公司 2021 年年度报告全文 以资本公积金转增股本。 第一节 重要提示、目录和释义 公司董事会、监事会及董事、监事、高级管理人员保证年度报告内容的真 实、准确、完整，不存在虚假记载、误导性陈述或者重大遗漏，并承担个别和 连带的法律责任。 公司负责人董凡、主管会计工作负责人何小莲及会计机构负责人(会计主管 人员)李紫芸声明：保证本年度报告中财务报告的真实、准确、完整。 所有董事均已出席了审议本报告的董事会会议。 公司需遵守《深圳证券交易所上市公司自律监管指引第 4 号——创业板行 业信息披露》中的"医疗器械业务"的披露要求。 本年度报告中涉及经营计划、未来计划、发展战略等前瞻性陈述，不构成 公司对投资者的实质承诺或盈利预测等，能否实现取决于市场状况变化等多种 因素，敬请广大投资者注意投资风险。 公司已在本报告中对公司未来发展可能面对的风险 ...